机构：[1]Beijing Key Laboratory of Pediatric Hematology Oncology，National Key Discipline of Pediatrics, Ministry of Education,Key Laboratory of Major Diseases in Children, Ministry of Education,Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China.医技科室职能科室临床流行病与循证医学中心血液中心首都医科大学附属北京儿童医院
The delay in platelet recovery after hematopoietic stem cell transplantation (HSCT) is closely related to the overall survival rate of transplanted children. The use of platelet-producing agents such as eltrombopag and romiplostim has made great progress in treating diseases such as immune thrombocytopenia and aplastic anemia. However, the use of such drugs in patients with thrombocytopenia after transplantation, especially in children, is rare. This study aimed to report eltrombopag treatment for 3 children with primary platelet engraftment failure and secondary thrombocytopenia after allogeneic HSCT. Of these patients, 2 had platelets stabilized at >= 50x10(9)/L after eltrombopag treatment and subsequent withdrawal of eltrombopag. All 3 patients showed no clear adverse reactions. The results indicated a wide application prospect of eltrombopag treatment in children with thrombocytopenia after allogeneic HSCT.
基金：
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Grant [ZY201404]; Beijing Municipal Administration of Hospitals DengFeng Program [DFL20151101]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81641006]; Beijing City Youth top-notch talents project [2016000021223ZK16]
第一作者机构：[1]Beijing Key Laboratory of Pediatric Hematology Oncology，National Key Discipline of Pediatrics, Ministry of Education,Key Laboratory of Major Diseases in Children, Ministry of Education,Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China.
通讯作者：
通讯机构：[1]Beijing Key Laboratory of Pediatric Hematology Oncology，National Key Discipline of Pediatrics, Ministry of Education,Key Laboratory of Major Diseases in Children, Ministry of Education,Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China.[*1]Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Department of Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, 56 Nanlishi Road, Beijing 100045, China
推荐引用方式(GB/T 7714)：
Li Sidan,Wu Runhui,Wang Bin,et al.Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children[J].JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY.2019,41(1):38-41.doi:10.1097/MPH.0000000000001263.
APA：
Li, Sidan,Wu, Runhui,Wang, Bin,Fu, Lingling,Zhu, Guanghua...&Qin, Maoquan.(2019).Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY,41,(1)
MLA：
Li, Sidan,et al."Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children".JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 41..1(2019):38-41
